ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 21, 2016--
BioTime, Inc. (NYSE MKT:BTX) today announced that it will host a
conference call on Thursday, March 31, to update investors on the
Company’s recent accomplishments and objectives for the remainder of
2016. Among the highlights of the call will be an update on the clinical
trials currently underway for Renevia® for lipoatrophy, and OpRegen® for
dry age-related macular degeneration. In addition, management will
discuss recent developments for its other clinical stage programs:
AST-VAC1 cancer immunotherapy for acute myeloid leukemia, AST-OPC1 for
spinal cord injury, and OncoCyte’s diagnostic programs in oncology.
BioTime will also review recent corporate transactions and
The BioTime conference call and webcast is scheduled for Thursday, March
31, 2016, and will begin at 4:30 p.m. Eastern / 1:30 p.m. Pacific.
Prepared remarks by management will be followed by a Q&A session with
analysts and institutional investors following the Company.
The conference call dial-in number in the U.S./Canada is (877) 407-0784.
For international participants outside the U.S./Canada, the dial-in
number is (201) 689-8560. For all callers, please refer to the “BioTime,
Inc. Corporate Update Conference Call.” The live webcast can be accessed
on the company’s website at http://www.biotimeinc.com/.
A replay of the conference call will be available for seven business
days beginning about two hours after the conclusion of the live call, by
calling toll-free (from U.S./Canada) (877) 870-5176; international
callers dial (858) 384-5517. Use the Conference ID 13633134.
Additionally, the archived webcast will be available at http://www.biotimeinc.com/.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what we
believe to be the world’s premier collection of pluripotent stem cell
assets. The foundation of our core therapeutic technology platform is
pluripotent stem cells that are capable of becoming any of the cell
types in the human body. Pluripotent stem cells have potential
application in many areas of medicine with large unmet patient needs,
including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike
pharmaceuticals that require a molecular target, therapeutic strategies
based on the use of pluripotent stem cells are generally aimed at
regenerating or replacing affected cells and tissues, and therefore may
have broader applicability than pharmaceutical products.
In order to efficiently advance product candidates through the clinical
trial process, we have historically created operating subsidiaries for
each program and product line. This approach has fostered efficient use
of resources and reduced shareholder dilution as compared to strategies
commonly deployed by the biotechnology industry, as the various programs
and product lines have advanced through basic research and animal
studies. We and our subsidiaries now have four therapeutic product
candidates in human clinical trials, each of which addresses a large
market opportunity. In addition to the development of therapeutics,
BioTime’s research and other activities have resulted, over time, in the
creation of other subsidiaries that address other non-therapeutic market
opportunities such as cancer diagnostics, drug development and stem cell
research products, and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160321005392/en/
Source: BioTime, Inc.
Dan L. Lawrence, 510-775-0510
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890